Biosimilars Council Launches Educational Research for Leading Biosimilar Research

Wednesday December 14, 2022

Washington, D.C. (December 14, 2022) – The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), today announced the launch of its “Research and Studies,” online resource. The new resource captures the growing body of scientific evidence on the safety, efficacy, and cost savings of biosimilar medicines.

“Biosimilar medicines are safe, effective, and more affordable treatment options for patients,” said Craig Burton, Executive Director of the Biosimilars Council. “But peer-reviewed studies can be time-consuming to sift through. We are proud to launch the Research and Studies resource to give patients, caregivers, health care providers, and policymakers an easy way to access important information about biosimilars.”

The Research and Studies page is easily navigable, allowing visitors to search for biosimilar studies across a range of relevant categories to easily find the information they need.

Click here to visit the Research and Studies page.


Susan Reilly

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



Register Now! February 5–7, 2024 | Tampa, Florida

AAM’s annual meeting Access! 2024 brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Discussions center around the business, breakthroughs and politics that shape our industry. It’s the opportunity to hear firsthand from world-renowned speakers and learn about where our industry is heading and what our future holds.